Statement of Changes in Beneficial Ownership (4)
March 02 2021 - 6:00PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
MACKENZIE ALEXANDER R |
2. Issuer Name and Ticker or Trading Symbol
PFIZER INC
[
PFE
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Executive Vice President |
(Last)
(First)
(Middle)
PFIZER INC.-CORP. SECRETARY, 235 EAST 42ND ST. |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/27/2021 |
(Street)
NEW YORK, NY 10017
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 2/27/2021 | | M | | 29838.0000 (1) | A | $22.3500 | 153338.0000 | D | |
Common Stock | 2/27/2021 | | F | | 5812.0000 (2) | D | $33.4900 (3) | 147526.0000 | D | |
Common Stock | 2/27/2021 | | F | | 18919.0000 (4) | D | $34.6400 (5) | 128607.0000 | D | |
Common Stock | | | | | | | | 10111.0000 | I | By Rule 16b-3 Plan |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Appreciation Rights | $22.3500 | 2/27/2021 | | M | | | 29838.0000 | 2/27/2021 | 2/27/2021 | Common Stock | 29838.0000 | $0.0000 | 0.0000 | D | |
Explanation of Responses: |
(1) | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
(2) | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
(3) | Price is the closing price of Pfizer common stock on February 26, 2021. |
(4) | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
(5) | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
Remarks: In connection with the completed spinoff and combination of the Upjohn business with Mylan to create Viatris, and in accordance with their terms, adjustments were made to stock units, by providing additional Pfizer total shareholder return units (Stock Appreciation Rights) to plan participants in lieu of the Viatris dividend provided to shareholders, in order to maintain the same value post-transaction as the value of the outstanding awards prior to the transaction (subject to rounding). |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
MACKENZIE ALEXANDER R PFIZER INC.-CORP. SECRETARY 235 EAST 42ND ST. NEW YORK, NY 10017 |
|
| Executive Vice President |
|
Signatures
|
Susan E. Grant, by power of atty., for Alexander R. MacKenzie | | 3/2/2021 |
**Signature of Reporting Person | Date |
Pfizer (NYSE:PFE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Sep 2023 to Sep 2024